Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9

I. Chih Chen, Wei Kung Tseng, Yi Heng Li, Shih Ya Tseng, Ping Yen Liu, Ting Hsing Chao

研究成果: Article

摘要

The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations. We performed a post hoc analysis of two prospective, double-blind, randomized controlled trials including 115 patients of whom 61 received cilostazol 200 mg/day and 54 received placebo for 12 weeks. Linear regression analysis was performed to determine the associations between several parameters and changes in PCSK9 levels. Use of cilostazol, but not placebo, significantly increased plasma PCSK9 concentrations, high-density lipoprotein cholesterol levels, and number of circulating endothelial progenitor cells (EPCs), and decreased triglyceride levels with a trend toward an increase in total cholesterol (TC) levels. A reduction in hemoglobin A1C and an increase in plasma vascular endothelial growth factor and adiponectin levels with cilostazol treatment were also found. Changes in the number of circulating EPCs were positively correlated and the TC concentrations were inversely correlated with changes in the PCSK9 levels. After adjusting for changes in levels of TC and numbers of circulating EPCs and history of metabolic syndrome, use of cilostazol remained independently associated with changes in plasma PCSK9 levels. In conclusion, cilostazol treatment was significantly and independently associated with an increase in plasma PCSK9 levels in patients with peripheral artery disease or at a high risk of cardiovascular disease regardless of background statin use and caused an improvement in some metabolic disorders and levels of vasculo-angiogenic biomarkers.

原文English
頁(從 - 到)108042-108053
頁數12
期刊Oncotarget
8
發行號64
DOIs
出版狀態Published - 2017 一月 1

指紋

Cholesterol
Placebos
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peripheral Arterial Disease
Adiponectin
cilostazol
Proprotein Convertase 9
HDL Cholesterol
Vascular Endothelial Growth Factor A
Linear Models
Atherosclerosis
Hemoglobins
Triglycerides
Homeostasis
Cardiovascular Diseases
Therapeutics
Randomized Controlled Trials
Biomarkers
Regression Analysis
Lipids

All Science Journal Classification (ASJC) codes

  • Oncology

引用此文

@article{45c007950a8a46e7ba3947e1e46d7726,
title = "Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9",
abstract = "The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations. We performed a post hoc analysis of two prospective, double-blind, randomized controlled trials including 115 patients of whom 61 received cilostazol 200 mg/day and 54 received placebo for 12 weeks. Linear regression analysis was performed to determine the associations between several parameters and changes in PCSK9 levels. Use of cilostazol, but not placebo, significantly increased plasma PCSK9 concentrations, high-density lipoprotein cholesterol levels, and number of circulating endothelial progenitor cells (EPCs), and decreased triglyceride levels with a trend toward an increase in total cholesterol (TC) levels. A reduction in hemoglobin A1C and an increase in plasma vascular endothelial growth factor and adiponectin levels with cilostazol treatment were also found. Changes in the number of circulating EPCs were positively correlated and the TC concentrations were inversely correlated with changes in the PCSK9 levels. After adjusting for changes in levels of TC and numbers of circulating EPCs and history of metabolic syndrome, use of cilostazol remained independently associated with changes in plasma PCSK9 levels. In conclusion, cilostazol treatment was significantly and independently associated with an increase in plasma PCSK9 levels in patients with peripheral artery disease or at a high risk of cardiovascular disease regardless of background statin use and caused an improvement in some metabolic disorders and levels of vasculo-angiogenic biomarkers.",
author = "Chen, {I. Chih} and Tseng, {Wei Kung} and Li, {Yi Heng} and Tseng, {Shih Ya} and Liu, {Ping Yen} and Chao, {Ting Hsing}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22448",
language = "English",
volume = "8",
pages = "108042--108053",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "64",

}

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. / Chen, I. Chih; Tseng, Wei Kung; Li, Yi Heng; Tseng, Shih Ya; Liu, Ping Yen; Chao, Ting Hsing.

於: Oncotarget, 卷 8, 編號 64, 01.01.2017, p. 108042-108053.

研究成果: Article

TY - JOUR

T1 - Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9

AU - Chen, I. Chih

AU - Tseng, Wei Kung

AU - Li, Yi Heng

AU - Tseng, Shih Ya

AU - Liu, Ping Yen

AU - Chao, Ting Hsing

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations. We performed a post hoc analysis of two prospective, double-blind, randomized controlled trials including 115 patients of whom 61 received cilostazol 200 mg/day and 54 received placebo for 12 weeks. Linear regression analysis was performed to determine the associations between several parameters and changes in PCSK9 levels. Use of cilostazol, but not placebo, significantly increased plasma PCSK9 concentrations, high-density lipoprotein cholesterol levels, and number of circulating endothelial progenitor cells (EPCs), and decreased triglyceride levels with a trend toward an increase in total cholesterol (TC) levels. A reduction in hemoglobin A1C and an increase in plasma vascular endothelial growth factor and adiponectin levels with cilostazol treatment were also found. Changes in the number of circulating EPCs were positively correlated and the TC concentrations were inversely correlated with changes in the PCSK9 levels. After adjusting for changes in levels of TC and numbers of circulating EPCs and history of metabolic syndrome, use of cilostazol remained independently associated with changes in plasma PCSK9 levels. In conclusion, cilostazol treatment was significantly and independently associated with an increase in plasma PCSK9 levels in patients with peripheral artery disease or at a high risk of cardiovascular disease regardless of background statin use and caused an improvement in some metabolic disorders and levels of vasculo-angiogenic biomarkers.

AB - The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations. We performed a post hoc analysis of two prospective, double-blind, randomized controlled trials including 115 patients of whom 61 received cilostazol 200 mg/day and 54 received placebo for 12 weeks. Linear regression analysis was performed to determine the associations between several parameters and changes in PCSK9 levels. Use of cilostazol, but not placebo, significantly increased plasma PCSK9 concentrations, high-density lipoprotein cholesterol levels, and number of circulating endothelial progenitor cells (EPCs), and decreased triglyceride levels with a trend toward an increase in total cholesterol (TC) levels. A reduction in hemoglobin A1C and an increase in plasma vascular endothelial growth factor and adiponectin levels with cilostazol treatment were also found. Changes in the number of circulating EPCs were positively correlated and the TC concentrations were inversely correlated with changes in the PCSK9 levels. After adjusting for changes in levels of TC and numbers of circulating EPCs and history of metabolic syndrome, use of cilostazol remained independently associated with changes in plasma PCSK9 levels. In conclusion, cilostazol treatment was significantly and independently associated with an increase in plasma PCSK9 levels in patients with peripheral artery disease or at a high risk of cardiovascular disease regardless of background statin use and caused an improvement in some metabolic disorders and levels of vasculo-angiogenic biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85037356805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037356805&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22448

DO - 10.18632/oncotarget.22448

M3 - Article

AN - SCOPUS:85037356805

VL - 8

SP - 108042

EP - 108053

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 64

ER -